Immunogen Inc $ 7.38 -0.27 (-3.53%)
Volume:
2,523,662
Avg Vol (1m):
2,486,949
Market Cap $:
1.44 Bil
Enterprise Value $:
1.27 Bil
P/E (TTM):
0.00
P/B:
0.00
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.63 | ||
| Equity-to-Asset | -0.17 | ||
| Debt-to-Equity | -0.58 | ||
| Debt-to-EBITDA | -0.54 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | -4.43 | ||
| Beneish M-Score | 33.88 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -52.94 | ||
| Net Margin % | -77.65 | ||
| ROA % | -27.16 | ||
| ROC (Joel Greenblatt) % | -219.1 | ||
| 3-Year Revenue Growth Rate | -7 | ||
| 3-Year EBITDA Growth Rate | 25.8 | ||
| 3-Year EPS without NRI Growth Rate | 25.2 |
IMGN
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 12.92 | ||
| EV-to-EBIT | -26.49 | ||
| EV-to-EBITDA | -27.83 | ||
| EV-to-Revenue | 13.94 | ||
| Current Ratio | 2.2 | ||
| Quick Ratio | 2.2 | ||
| Days Sales Outstanding | 20.17 | ||
| Days Payable | 32.19 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Median-PS-Value | 1.06 | ||
| Earnings Yield (Greenblatt) % | -3.78 |